Division of Gastroenterology and Hepatology, University of Alabama, 1720 2nd Avenue South, BDB 380, Birmingham, AL 35233, USA.
Division of Gastroenterology and Hepatology, University of Chicago, Center for Liver Diseases, The University of Chicago Biological Sciences, 5841 South Maryland Avenue, Room M-454, Chicago, IL 60637, USA.
Clin Liver Dis. 2018 Feb;22(1):201-211. doi: 10.1016/j.cld.2017.08.014.
Although hepatocellular carcinoma (HCC) is more common in the setting of cirrhosis, there is increasing evidence that it can develop in the setting of noncirrhotic nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) and that steatosis alone can promote carcinogenesis. In addition, obesity, diabetes, and metabolic syndrome are recognized risks for the development of HCC. A better understanding of the mechanisms involved in the development of NAFLD/NASH-related HCC will allow the discovery of new targets for therapeutic and preventive intervention. The surveillance for HCC in the setting of noncirrhotic NAFLD/NASH, obesity, diabetes, and metabolic syndrome remains an area of uncertainty.
虽然肝细胞癌(HCC)在肝硬化的背景下更为常见,但越来越多的证据表明,它也可以在非肝硬化的非酒精性脂肪性肝病(NAFLD)/非酒精性脂肪性肝炎(NASH)的背景下发生,而且单纯的脂肪变性也可以促进癌变。此外,肥胖、糖尿病和代谢综合征是 HCC 发生的公认危险因素。更好地了解非酒精性脂肪性肝病/非酒精性脂肪性肝炎相关 HCC 发生的机制将有助于发现治疗和预防干预的新靶点。在非肝硬化的非酒精性脂肪性肝病/非酒精性脂肪性肝炎、肥胖、糖尿病和代谢综合征背景下 HCC 的监测仍然是一个不确定的领域。
World J Gastroenterol. 2015-4-14
Annu Rev Med. 2015-10-14
Zhonghua Gan Zang Bing Za Zhi. 2016-2
Metabolism. 2016-8
Clin Liver Dis. 2015-12-24
Cancers (Basel). 2024-5-12
Acta Endocrinol (Buchar). 2023
Cell Mol Life Sci. 2023-10-5
Am J Cancer Res. 2023-7-15
Clin Gastroenterol Hepatol. 2024-2